Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy

Guglielmo Dini, Alessandra Toletone, Ilaria Barberis, Nicoletta Debarbieri, Emanuela Massa, Chiara Paganino, Francesca Bersi, Alfredo Montecucco, Cristiano Alicino, Paolo Durando, Guglielmo Dini, Alessandra Toletone, Ilaria Barberis, Nicoletta Debarbieri, Emanuela Massa, Chiara Paganino, Francesca Bersi, Alfredo Montecucco, Cristiano Alicino, Paolo Durando

Abstract

Vaccination against Hepatitis B Virus (HBV) became mandatory in Italy for all newborns and 12 years-old individuals in the 1991. The immunogenicity of HBV vaccine and the effectiveness of the universal immunization strategy have been widely demonstrated. However the need to assess the antibody concentrations above the well known serological correlate of protection for HBV infection (≥10 mIU/mL), established in individuals immunized with a 3 doses vaccination course, is still recommended in subjects exposed to occupational risks in different settings, particularly the healthcare services. This practice has to be performed during the preventive medical examination, before the worker's exposure to biological hazards, as a fundamental part of Occupational Health Surveillance Programs in several Countries, including Italy: the goal is to assure individual protection, also providing booster doses when needed, after many years following the primary vaccination. During the 2011-2013 period, an observational study was performed in Healthcare students (HCSs) trained at a regional university acute-care hospital in North-Western Italy, properly immunized against HBV during infancy or adolescence, in order to evaluate the persistence of seroprotection and to assess the anamnestic response to booster vaccination. Data from 717 subjects undergoing HbsAg Ab and HBc Ab testing during the preventive medical examination, and receiving a booster dose of HBV vaccine when resulting with a non-protective titer (<10 mIU/mL), were collected and analyzed. Most of the HCSs (74.6%) included in the survey, mean age 24.8 y ( ± 4.6 SD), had received the primary vaccination course during the first year of life (3-5-11 months). Globally, 507 (70.7%) HCSs showed protective antibody titres, and an anamnestic response was observed in more than 95% subjects receiving the booster dose. Our study demonstrated the long-term persistence of protection of HBV vaccine, more than 20 y following the primary immunization, in HCSs who are exposed to occupational health risk. The anamnestic response observed in non-seroprotected subjects who received the booster further confirms the capability of the HBV vaccine to create a strong immunological memory.

Keywords: Hepatitis B Virus (HBV); anamnestic response; occupational health surveillance programs; persistence of protection; vaccine.

References

    1. Zanetti AR. Update on hepatitis B vaccination in Italy 10 years after its implementation. Vaccine 2001. March 21; 19(17–19):2380-3; PMID:11257364;
    1. Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, Santonastasi F, Marzolini A, Ciccozzi M, Moiraghi A. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000; 33(6):980-5; PMID:11131462;
    1. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, Trivello R. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004; 22:607-610; PMID:14741151;
    1. Italian Law, May 27 1991 No.165: Compulsory vaccination against hepatitis B virus. Available from: (last access on: 18 August 2016).
    1. Piazza M, Da Villa G, Picciotto L, Abrescia N, Guadagnino V, Memoli AM, Vegnente A, Iorio R, Cimmino L. Mass vaccination against hepatitis B in infants in Italy. Lancet 1988; 2(8620):1132; PMID:2903337;
    1. Mele A, Stroffolini T, Zanetti AR. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J Med Virol 2002; 67(3):440-3. Review; PMID:12116041;
    1. Heininger U, Gambon M, Gruber V, Margelli D. Successful hepatitis B immunization in non- and low responding health care workers. Hum Vaccin 2010; 19(9):6.
    1. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, de Perio MA, Reilly M, Byrd K, Ward JW. Centers for Disease Control and Prevention (CDC). CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 2013; 62(RR-10):1-19; PMID:24352112
    1. Lewis JD, Enfield KB, Sifri CD. Hepatitis B in healthcare workers: Transmission events and guidance for management. World J Hepatol 2015; 7(3):488-97; PMID:25848472;
    1. Lamberti M, De Rosa A, Garzillo EM, Corvino AR, Sannolo N, De Pascalis S, Di Fiore E, Westermann C, Arnese A, Gabriella DG, et al.. Vaccination against hepatitis b virus: are Italian medical students sufficiently protected after the public vaccination programme?. J Occup Med Toxicol 2015; 10:41; Erratum in: J Occup Med Toxicol. 2016;11:3; PMID:26539242;
    1. Italian Law decree n. 81 of 9h April 2008. Available from: (last access on 18 August 2016).
    1. Bonanni P, Bonaccorsi G. Vaccination against hepatitis B in health care workers. Vaccine 2001; 19(17–19):2389-94; PMID:11257366;
    1. Italian Ministry of Health National Vaccination Prevention Plan 2012-2014. Available from: (last access on 18 August 2016).
    1. Zaffina S, Marcellini V, Santoro AP, Scarsella M, Camisa V, Vinci MR, Musolino AM, Nicolosi L, Rosado MM, Carsetti R. Repeated vaccinations do not improve specific immune defenses against Hepatitis B in non-responder health care workers. Vaccine 2014; 32(51):6902-10; PMID:25444815;
    1. Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, et al.. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27:3459-3462; PMID:19200823;
    1. Zanetti AR. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010; 10(11):755-6 ; PMID:20884297;
    1. Gabutti A, L Romanò, Blanc P, Meacci F, Amendola A, Mele A, Mazzotta F, Zanetti AR. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25:3129-32; PMID:17291637;
    1. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, et al.. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366(9494):1379-84; PMID:16226616;
    1. Chiara F, Bartolucci GB, Cattai M, Piazza A, Nicolli A, Buja A, Trevisan A. Hepatitis B vaccination of adolescents: significance of non-protective antibodies. Vaccine 2013; 32(1):62-8); PMID:24188755;
    1. Coppola N, Corvino AR, De Pascalis S, Signoriello G, Di Fiore E, Nienhaus A, Sagnelli E, Lamberti M. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC Infect Dis 2015; 15:149; PMID:25884719;
    1. Chiara F, Bartolucci GB, Mongillo M, Ferretto L, Nicolli A, Trevisan A. Hepatitis B vaccination at three months of age: a successful strategy?. Vaccine 2013; 31(13):1696-700.
    1. Stroffolini T, Guadagnino V, Caroleo B, De Sarro G, A Focà, Liberto MC, Giancotti A, Barreca GS, Marascio N, Lombardo FL, et al.. Long-term immunogenicity of hepatitis B vaccination in children and adolescents in a southern Italian town. Infection 2012; 40(3):299-302; PMID:22173948;
    1. Spada E, L Romanò, Tosti ME, Zuccaro O, Paladini S, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, et al.. Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-up study. Clin Microbiol Infect 2014; 20(10):O680-6; PMID:24528380;
    1. Poorolajal J, Hooshmand E. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev 2016; 7(6):CD008256 Review.
    1. Rosenberg C, Bovin NV, Bram LV, Flyvbjerg E, Erlandsen M, Vorup-Jensen T, Petersen E. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. Hum Vaccin Immunother 2013; 9(7):1466-76; PMID:23571167;
    1. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC) Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR-7):1-45.
    1. Italian Law decree n. 196, 30 June 2003 (article 24) Available from: (last access on 18 August 2016).

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj